Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new cancer treatments and specialized in protein interactions, announces today preclinical results demonstrating the potential of inecalcitol alone and in a synergistic combination with a cytotoxic platinum derivative, to inhibit the growth of a human hormone-dependent prostate cancer cell line.
Read more...